Zusammenfassung
Was ist Neuroprotektion? Eine einleuchtende Definition neuroprotektiver Strategien wurde von Ira Shoulson gegeben[23]:„Neuroprotective strategies ate pharmacological interventions that produce enduring benefits by favourably influencing underlying etiology or pathogenesis and thereby forestalling onset of disease or clinical decline“. Es handelt sich bei dieser Definition um eine Herangehenweise an Neuroprotektion, die sich vor allem auf pharmakologische Strategien erstreckt. Dies schießt keine Strategien mit ein, die allein der Prävention dienen; so zum Beispiel die Phenylalaninrestriktion in der Behandlung der Phenylketonurie, die Behandlung des M. Wilson mit Chelatoren oder gar die Polioimpfung, die ja eindrucksvoll vor dem verlust von Motoneuronen schützt. Darüber hinaus bedeutet das Wort „enduring“, dass sich diese Strategien von rein symptomatischen Therapieansätzen wie der L-Dopa-Therapie des M. Parkinson unterscheiden. Schließlich fordert diese Definition, dass neuroprotektive Strategien entweder die Ätiologie oder die Pathogenese degenerativer Erkrankungen beeinflussen, also eine besonderes hohe Hürde dar, da wir bei vielen degenerativen Erkrankungen des zentralen Nervensystems die Ursache nur inkomplett kennen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, Hodges JR, Rosser AE, Wood NW, Brooks DJ (1999) Huntington’s disease progressions. Brain 122: 2353–2363
Bensimon G, Lacomblez L, Meininger V and the ALS/Riluzole Study Group (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330: 585–591
Bensimon G, Leigh PN, Ludolph A, Lacomblez L, Vidailhet M; Landwehrmeyer B, Burn D, Dib M, Zierz S, Meininger V, Lees A, Agid Y & The NNIPPS Study Group (2002) Neuroprotection and natural history in Parkinson Plus Syndromes (NNIPPS): Design & progress report of a clinical trial of the efficacy and safety of riluzole in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). International Movement Disorders Congress, Miami
Foltynie T, Brayne C, Barker RA (2002) The heterogenity of idiopathic Parkinson’s disease. J Neurol 249: 138–145
Gurney ME, Pu H, Chiu A, Dal Canto M, Polchow C, Alexander D, Caliendo J, Hantati A, Kwon Y, Deng H, Chen W, Zhai P, Sifit R, Siddique T (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1773–1775
Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39: 147–157
Huang S, Li B, Gray MD, Oshima J, Mian IS, Campisi J (1998) The premature ageing syndrome protein, WRN, is a 3’-5’exonuclease. Nature Genetics 20: 114–116
Karitzky J, Ludolph AC (2001) Imaging and Neurochemical Markers for Diagnosis and Disease Progression in ALS, J Neurol Science (191): 35–41
Kong J, Xu Z (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 8: 3241–3250
Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425–1431
Lynch DR, Farmer JM, Balcer LJ, Wilson RB (2002) Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 58: 743–747
Martin GM, Oshima J (2000) Lessons from human progeroid syndromes. Nature 408: 263–269
Morrish PK, Sawle GV, Brooks DJ (1996) An (18F)dopa PET and clinical study of the rate of progression in Parkinson’s disease. Brain 119: 585–591
Morrison JH, Hof PR (1997) Life and death of neurons in the aging brain. Science 278: 412–419
Mouradian MM (2002) Recent advances in the genetics and pathogenesis of Parkinson’s disease. Neurology 58: 179–185
Munch C, Zhu BG, Schwalenstocker B, Seefried U, Ludolph AC, Meyer T (2001) Regulation of RNA splicing of the glutamate transporter EAAT2 in the preclinical course of a transgenic mouse model for amyotrophic lateral sclerosis. Journal of Neurochemistry
Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson’s disease progression. JAMA 287: 1653–1661
Price DL, Sisodia SS, Borchelt DR (1998) Genetic neurodegenerative diseases: The human illness and transgenic models. Science 282: 1079–1083
Riviere M, Meininger V, Zeisser P, Munsat T (1998) An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 55: 526–528
Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62
Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A (1999) Effect of idebenone on cardiomyopathy in Friedreich’s ataxia: a preliminary study. Lancet 354: 477–479
Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, Tatsch K (2000) Striatal dopamine transporter binding assessed by (I-23)IPT and single photon emission computed tomography in patients with early Parkinson’s disease: Implications for a preclinical diagnosis. Arch Neurol 57: 205–208
Shoulson I (1998) Experimental therapeutics of neurodegenerative disorders: unmet needs. Science 282: 1072–1074
Sleegers K, Van Duijn CM (2001) Alzheimer’s Disease: Genes, Pathogenesis and Risk Prediction. Community Genet 4: 197–203
Storch A, Burkhardt K, Ludolph AC, Schwarz J (2000) Protective effects of riluzole on dopamine neurons: Involvement of oxidative stress and cellular energy metabolism. J Neurochem 75: 2259–2269
The EHDI Trial Group: the effect of riluzole 50 mg BID over a period of three years on the progression of Huntington’s disease. Protocol. Submitted
Traynor BJ, Alexander M, Corr B, Frost E, Mahon L, Hardman 0 (2001) Riluzole and prognosis in amyotrophic lateral sclerosis: Findings of the Irish amyotrophic lateral sclerosis register over a five year study period 1995–2000. ALS and other motor neuron disorders 2 (Suppl 2): 1995–2000
Tumani H, Windl O, Kretzschmar HA, Ludolph AC (2001) Die klinisch atypische CJK - Diagnostische Bedeutung von Liquormarkern und molekulargenetischen Untersuchungen? Deutsche Medizinische Wochenschrift 127: 317–320
Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A (2002) Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. ALS and other motor neuron disorders 3: 15–21
Vogt C, Vogt O (1922) Erkrankungen der Groghirnrinde. Journal fur Psychologie und Neurologic 28: 8–171
von Arnim C, Ludolph AC (2001) Normales und pathologisches Altern des Gehirns. Fortschr Med 118: 165–168
Whone AL, Remy P, Davis MR, Sabolek M, Nahmias C, Stoessl J, Watts RL, Brooks DJ (2002) The REAL-PET Study: slower progression in early Parkinson’s disease treated with ropinirole compared with L-dopa. Neurology 59: A82–A83
Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 101: 57–66
Xu Z (2000) Mechanism and treatment of motoneuron degeneration in ALS: What have SOD1 mutants told us? ALS and other motor neuron disorders 1: 225–234
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ludolph, A.C. (2003). Neuroprotektive Strategien bei neurodegenerativen Erkrankungen — was haben wir gelernt?. In: Przuntek, H., Müller, T. (eds) Morbus Parkinson. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57362-0_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-57362-0_10
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-7985-1422-5
Online ISBN: 978-3-642-57362-0
eBook Packages: Springer Book Archive